← Leaderboards
Diwakar Davar
University Of Pittsburgh At Pittsburgh
$3,640,421
Attributed
$7,280,842
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,280,842 · 2
By mechanism
U01$4,722,849 · 1
R01$2,557,993 · 1
Top collaborators
- Hassane M Zarour5 shared
- Amanda G Paulovich4 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Hassane M Zarour$16,372,397
- John Munn Kirkwood$15,450,309
- Michael T Lotze$5,139,928
- Greg M. Delgoffe$10,560,525
- Lisa Helene Butterfield$10,558,896
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseImmune Checkpoint BlockadeProgrammed Cell Death Protein 1TumorImmunotherapy TrialsCombination ImmunotherapyImmunologicsMelanomaToxic EffectClinical TrialsResistanceAnti-Pd1 AntibodiesImmunotherapyClinical DevelopmentAdjuvant StudyClinical EfficacyAnti-Pd-1AgonistClinicB-LymphocytesAffectCd8-Positive T-LymphocytesCancer VaccinesAntigen Presentation
Grant awards (9)
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies$1,190,547
U01 · FY2025 · CA
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma$481,846
R01 · FY2025 · CA
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies$1,122,409
U01 · FY2024 · CA
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma$457,754
R01 · FY2024 · CA
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies$1,156,887
U01 · FY2023 · CA
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma$534,470
R01 · FY2023 · CA
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies$1,253,006
U01 · FY2022 · CA
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma$531,996
R01 · FY2022 · CA
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma$551,927
R01 · FY2021 · CA